Who is sponsoring NCT03965481?

NCT03965481 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03965481?

Interventions in NCT03965481: Dynamic Enhanced CT, Magnetic Resonance Imaging, Positron Emission Tomography.

What condition does NCT03965481 study?

NCT03965481 studies Malignant Ovarian Neoplasm, Ovarian Carcinoma.

Is NCT03965481 still recruiting?

NCT03965481 is currently active, enrolled. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT03965481

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer

Active, enrolled NA Last updated 15 April 2026

What this trial tests

NA trial testing Dynamic Enhanced CT in Malignant Ovarian Neoplasm in 21 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

12 May 2018

Primary endpoint
30 April 2027

30 April 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	21
Start date	12 May 2018
Primary completion	30 April 2027
Estimated completion	30 April 2027
Sites	1 location across United States

Drugs / interventions tested

Dynamic Enhanced CT
Magnetic Resonance Imaging
Positron Emission Tomography

Conditions studied

Malignant Ovarian Neoplasm — all drugs for Malignant Ovarian Neoplasm →
Ovarian Carcinoma — all drugs for Ovarian Carcinoma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, female only, with Malignant Ovarian Neoplasm or Ovarian Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies how well positron emission tomography/magnetic resonance (PET/MR) versus contrast enhanced computerized tomography (CECT) scans work in locating ovarian cancer tumors in patients with known or suspected ovarian cancer. PET, MR, and CECT scans use different methods to create images of areas inside the body. This trial is being done to see if PET/MR scans may help doctors locate ovarian cancer tumors, predict how well these tumors may be removed during surgery, and predict how patients respond to platinum-based chemotherapies compared to standard of care CECT scans.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Update on PET/MRI in Gynecological Malignancies-A Review of the Literature.
Virarkar M, Vulasala SS, Calimano-Ramirez L, Singh A, et al · · 2023 · cited 5× · PMID 36661732 · DOI 10.3390/curroncol30010083

Verify or expand the search:

Other recruiting trials for Malignant Ovarian Neoplasm

Currently open trials in the same condition.

NCT00488878 — Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03965481 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03965481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing